Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | POLG | P54098 | 2/20 | 0.38 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11718779 | 0.98 | LMNA (0.45) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL11715163 | 0.98 | LMNA (0.45) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL3703275 | 0.96 | LMNA (0.46) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL11716186 | 0.93 | LMNA (0.48) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL27292843 | 0.85 | HTR3E (0.40) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL26171208 | 0.85 | PDE3A (0.43) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL27283810 | 0.83 | HTR3E (0.44) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL4919650 | 0.81 | LMNA (0.43) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL9310528 | 0.77 | LMNA (0.54) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL22198551 | 0.77 | LMNA (0.40) | LMNAPDE3ACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161726-B2 | Biomimetic vesicles and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-10 | — | — | US | claimed |
| US-20230346972-A1 | BIOMIMETIC VESICLES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2023-11-02 | — | — | US | claimed |
| US-20210205473-A1 | BIOMIMETIC VESICLES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2021-07-08 | — | — | US | claimed |
| EP-3796895-A1 | BIOMIMETIC VESICLES AND USES THEREOF | Ohio State Innovation Foundation (US) | 2021-03-31 | — | — | EP | claimed |
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20050049220-A1 | Dosing regimen for Flaviviridae therapy | PHARMASSET, INC. | 2005-03-03 | — | — | US | claimed |
| WO-2005018330-A1 | DOSING REGIMEN FOR FLAVIVIRIDAE THERAPY | PHARMASSET, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-1997048391-A2 | METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 1997-12-24 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-4746875-A2 | CARCINOGENESIS REDUCTION WITH PENTAAZA MACROCYCLIC RING COMPLEX | Galera Labs, LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122074087-A | Reverse transcription mediated gene editing system and use thereof | 阿伯生物技术公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-04-23 | — | — | US | disclosed |
| WO-1997048391-A2 | METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 1997-12-24 | — | — | WO | disclosed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4016267-A | BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | CYP4X1, SLC6A7, ZFX | LMNA 3499/4885PDE3A 2439/4885CACNA1F 122/4885 |
| US-20050049220-A1 | Dosing regimen for Flaviviridae therapy | HAVCR2, EIF2AK2, CYP3A5 | LMNA 3687/4885PDE3A 2979/4885CACNA1F 4820/4885 |
| US-20260137817-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | LMNA 3759/4885PDE3A 4719/4885CACNA1F 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.